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Abstract
Background: Platelets play an important role in ischemic stroke. GPIba is a major platelet receptor that is critical
for platelet adhesion to exposed subendothelial matrix components at sites of vascular damage.
Methods: In this study, we used transgenic mice in which the extracellular part of GPIba is replaced by human
interleukin 4-receptor (GPIba/IL4Ra). We observed normal brain vasculature in these mice. We compared infarct
size in GPIba/IL4Ra and wild-type (WT) mice 23 hours after 1-hour transient middle cerebral artery occlusion
(tMCAO). In addition, the functional outcome was evaluated using a modified Bederson score.
Results: We found a significantly smaller infarct size in GPIba/IL4Ra mice compared to WT mice (38.0 ± 6.5 mm
3
vs. 74.2 ± 8.6 mm
3, p < 0.001). The decrease in infarct size was functionally relevant as indicated by a significantly
better functional Bederson score in GPIba/IL4Ra mice compared to WT animals (1.3 ± 0.4 vs. 2.7 ± 0.3, p < 0.05).
Conclusions: Our data illustrate and further confirm the important role of platelet GPIba in ischemic stroke,
suggesting that targeted inhibition of this receptor may open new avenues in stroke treatment.
Background
Stroke is one of the leading causes of death worldwide
with limited treatment options [1]. Platelets play a pivotal
role in cerebral ischemia/reperfusion injury by adhering
to the damaged vessel wall, leading to further platelet
recruitment and thrombus formation. The glycoprotein
(GP) Ib-IX-V complex is a crucial platelet receptor for
initial tethering and adhesion at sites of vascular injury.
This abundant complex on the platelet surface (12,500
copies per cell) consists of the leucine-rich repeat glyco-
proteins GPIba,G P I b b, GPIX and GPV in a 2:2:2:1 ratio
[2]. The adhesive function of GPIb-IX-V is mainly attrib-
uted to the interaction of GPIba with its major ligand
von Willebrand factor (VWF), exposed upon vascular
damage. The central role of the GPIba-VWF interaction
in mediating initial platelet adhesion is illustrated by the
bleeding disorders Bernard Soulier syndrome [3] and von
Willebrand disease [4], caused by deficiency of GPIb-IX-
V or VWF respectively. Besides its interaction with VWF,
GPIba can also engage counter-receptors such as aMb2
(Mac-1) on neutrophils and P-selectin on activated plate-
lets or endothelial cells [2]. Other GPIba ligands include
a-thrombin, clotting factors XI and XII, thrombospon-
din-I and high molecular weight kininogen [2]. Not sur-
prisingly, the importance of GPIba far exceeds that of
VWF in arterial thrombosis [5]. Thus, by binding a vari-
ety of ligands, GPIba is a central receptor in different
vascular processes of thrombosis and inflammation, all of
which may contribute to the progression of ischemic
stroke. Here, we studied stroke development in trans-
genic mice expressing GPIba in which the extracellular
domain was replaced by an isolated domain of the a-sub-
unit of the human IL-4 receptor [6]. We found that these
mice had better stroke outcome, as evidenced by smaller
infarct volumes and better functional scores.
Methods
Animals
GPIba/IL4Ra mice [6] and wild-type (WT) type mice
(Jackson Laboratory, Bar Harbor, ME) were 8-10 weeks
old males on C57BL/6J background. All experimental pro-
cedures were approved by the Animal Care and Use Com-
mittee of the Immune Disease Institute (Boston, USA).
Assessment of the cerebral vasculature
For assessment of the cerebral vasculature, animals were
deeply anesthetized with isoflurane and transcardially
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5 ml of black ink. Brains were carefully removed, fixed
in 4% PFA and the Circle of Willis and major arteries
were examined under a dissecting microscope. The
development of the posterior communicating arteries
(PComAs) was examined and scored as described [7].
Platelet counts
To measure platelet counts, blood was collected on
EDTA using coated capillaries via retro-orbital puncture.
Platelet count in whole blood was determined using a
Beckman Coulter AcT Diff 2 Hematology analyzer.
Induction of cerebral ischemia
Focal cerebral ischemia was induced by 60 min transient
middle cerebral artery occlusion (tMCAO) as described
[8-10]. Mice were anesthetized with 2% isoflurane/oxy-
gen mixture. Following a midline skin incision in the
neck, the proximal common carotid artery, and the
external carotid artery were ligated, and a standardized
silicon rubber-coated 6.0 nylon monofilament (6021;
Doccol Corp., Redlands, CA) was inserted and advanced
via the right internal carotid artery to occlude the origin
of the right MCA. Operation time per animal did not
exceed 15 minutes. The intraluminal suture was left in
situ for 60 minutes. Then, animals were re-anesthetized,
and the occluding monofilament was withdrawn to
allow reperfusion.
Some animals were exclusively used for laser-Doppler
flowmetry (Periflux 5000, Perimed, Kings Park, NY) to
monitor regional cerebral blood flow (rCBF) in the
MCA territory (6 mm lateral and 2 mm posterior from
bregma).
Mice were excluded from analysis when death
occurred within 24 h after tMCAO or when subarach-
noid hemorrhage was mascroscopically observed during
brain harvesting. No difference in exclusion rates
between the two groups was observed.
Assessment of infarct volume
Mice were sacrificed 24 hours after tMCAO. Brains were
quickly removed and cut into 2-mm-thick coronal sections
using a mouse brain slice matrix. The slices were stained
with 2% 2,3,5-triphenyl-tetrazolium chloride (TTC; Sigma-
Aldrich, St. Louis, MO) in PBS to visualize the infarctions.
Sections were photographed with a digital Nikon D70
camera and infarct areas (white) were measured by a
blinded rater using Image J software (National Institutes of
Health; http://rsbweb.nih.gov/ij).
Assessment of functional outcome
Neurological function was assessed, blinded for the mouse
genotype, 24 h after tMCAO, using the modified Bederson
score [11]. This test determines global neurological
function according to the following scoring system: 0, no
deficit; 1, forelimb flexion; 2, decreased resistance to lateral
push; 3, unidirectional circling; 4, longitudinal spinning; 5,
no movement.
Statistical analysis
For statistical analysis the unpaired 2-tailed t-test was
used (PrismGraph 4.0 software package, La Jolla, CA).
The Mann-Whitney U-test was used for analyzing the
Bederson score. P values less than 0.05 were considered
statistically significant. Results are shown as mean ± SD.
Results
GPIba/IL4Ra and WT animals have comparable cerebral
vasculature and regional cerebral blood flow
Upon assessment of the cerebral vasculature in WT (n =
5) and GPIba/IL4Ra (n = 3) mice, no major anatomic
differences were observed which could influence stroke
outcome (Figure 1A). The circle of Willis and the distri-
bution of the MCA trunk and branch appeared to be
anatomically identical between the genotypes. In addi-
tion, the score assessing formation of the posterior com-
municating arteries of both hemispheres, which can
influence susceptibility to tMCAO, did not differ signifi-
cantly (1.8 ± 0.4 for WT versus 1.7 ± 0.3 for GPIba/
IL4Ra mice, p = 0.82, Figure 1B).
To compare rCBF in the right MCA territory, laser
doppler flowmetry in WT (n = 5) and GPIba/IL4Ra (n =
3) was monitored at baseline levels, after insertion of the
occluding filament (ischemia) and 15 minutes after
removal of the filament (reperfusion). After advancing
the filament, the decrease in rCBF was similar between
WT and GPIba/IL4Ra animals, indicating comparable
occlusion of the MCA origin (7.8 ± 4.8% of baseline level
in WT mice versus 8.8 ± 1.8% of baseline level in GPIba/
IL4Ra mice, p = 0.88, Figure 1C). Fifteen minutes after
reperfusion, rCBF was reconstituted in all animals to >
70% of baseline levels and again did not significantly dif-
fer between WT and GPIba/IL4R animals (80.9 ± 6.6%
of baseline level in WT mice versus 77.4 ± 3.4% of base-
line level in GPIba/IL4Ra mice; p = 0.69, Figure 1C). Pla-
telet counts of GPIba/IL4Ra mice (664 ± 31 × 10
3/μl,
n = 6) were slightly lower than in WT animals (822 ±
62 × 10
3/μl, n = 9) although this difference was not sig-
nificant (p = 0.071, Figure 1D).
GPIba/IL4Ra animals have a better outcome after tMCAO
To investigate the role of GPIba-mediated interactions
in ischemic stroke, infarct sizes of GPIba/IL4Ra (n = 7)
and WT mice (n = 12) were compared after one hour
tMCAO and 23 hours of reperfusion. Interestingly, we
found that GPIba/IL4Ra mice had a ~50% reduction in
infarct size compared to WT animals (38.0 ± 6.5 mm
3
versus 74.2 ± 8.6 mm
3, p < 0.05, Figure 2A). The
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shown by a significantly better outcome in the Bederson
test for the GPIba/IL4Ra mice compared to WT mice
(1.3 ± 0.4 versus 2.7 ± 0.3, p < 0.05, Figure 2B). Taken
together, these results indicate that the GPIba receptor
is critically involved in cerebral ischemia/reperfusion
injury during stroke.
Discussion
We here report that mice lacking the extracellular part
of GPIba are protected from ischemic stroke as evi-
denced by 50% smaller infarct volumes and significantly
better neurologic outcome when compared to WT mice.
These results further establish the notion that GPIba is
critically involved in the pathogenesis of ischemic stroke
Figure 1 Regional cerebral blood flow and cerebral vasculature in WT and GPIba/IL4Ra mice. (A) Representative stainings of cerebral
vasculature by black ink perfusion of WT and GPIba/IL4Ra mice. (B) Score assessing the posterior communicating arteries perfusion of WT (n =
5) and GPIba/IL4Ra mice (n = 3). (C) Regional cerebral blood flow of the right middle cerebral artery territory of WT (n = 5) and GPIba/IL4Ra
mice (n = 3), measured at baseline, during occlusion and 15 min after reperfusion (reperfusion). (D) Platelet counts of WT (n = 9) and GPIba/
IL4Ra mice (n = 6). No statistically significant differences were observed in all parameters (A-D).
Figure 2 Infarct volumes and functional outcomes 23 hours after transient middle cerebral artery occlusion in WT and GPIba/IL4Ra
mice. (A) Representative 2,3,5-TTC stains of 3 corresponding coronal brain sections of wild type (left) and GPIba/IL4Ra (right) mice 23 h after
tMCAO (top) and brain infarct volumes of the 2 groups as measured by planimetry 23 h after tMCAO (bottom, n = 12 and 7 respectively). (B)
Neurologic Bederson score of WT and GPIba/IL4Ra mice as assessed at day 1 after tMCAO (n = 12 and 7 respectively) ** p< .001, *p< .05.
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study using the same mouse tMCAO model in which an
anti-GPIba monoclonal antibody was used to block the
GPIba receptor [14]. Use of this antibody led to a 60%
reduction of infarct volumes compared to control mice,
which was accompanied by a significant reduction in
neurologic deficits [14]. We recently demonstrated that
VWF deficient mice were protected from ischemic
stroke [8,15]. Since VWF is the main ligand of GPIba
on platelets, our data support the notion of a pathophy-
siological role for the GPIba-VWF interaction in stroke,
although we can not rule out that other GPIba-
mediated interactions are also important and abrogated
in GPIba/IL4Ra m i c e .I nf u l ls u p p o r to ft h i s ,w e
showed that VWF-deficient mice that were reconstituted
with a VWF mutant defective in binding to GPIba
retained their protection against stroke [9]. Moreover,
several conditions, including the GPIba Kozak poly-
morphism [16], GPIba variants with increased binding
to VWF [17] and high VWF levels [18,19], have all been
reported to be associated with an increased risk of
ischemic stroke in humans.
It has to be noted that GPIba/IL4Ra mice were
reported to have slightly reduced platelet counts [6].
Although not significant, also our measurements indicate
a slightly lower platelet count in GPIba/IL4Ra mice
compared to WT animals. Whereas we cannot comple-
tely exclude any effect of this small platelet count differ-
ence on stroke outcome, we believe that this is unlikely
to cause the observed dramatic protection against stroke.
Platelet adhesion to ferric chloride-treated mesenteric
arterioles was virtually absent in GPIba/IL4Ra mice,
resulting in the complete abrogation of thrombus forma-
tion [5]. VWF-deficient mice are still able to form
thrombi in this model, although thrombus formation is
significantly delayed [20,21]. Although these studies
showed that ligands other than VWF can support
GPIba-dependent platelet adhesion, interfering with the
binding of GPIba to VWF has indeed been proven to
have a profound antithrombotic effect [22-24]. Since an
increasing amount of evidence suggests that GPIba and
VWF could also mediate inflammatory processes, further
studies are needed to establish whether inhibition of
these molecules also reduce inflammation in stroke [25].
The search for safe and efficient drugs for stroke man-
agement has been hampered by an unacceptable risk of
fatal bleeding as seen e.g. with platelet aggregation inhibi-
tors [26]. In this respect, it is encouraging that we did not
observe intracranial hemorrhages after stroke in GPIba/
IL4Ra mice. Also in VWF deficient mice, no increased
bleeding was noticed in the tMCAO model [8,9,15]. In
comparison with inhibition of platelet aggregation, neu-
tralizing the VWF-GPIba-axis has been shown to have a
better benefit-to-risk ratio with respect to bleeding in
v a r i o u sm o d e l so fe x p e r i m e n t a lt h r o m b o s i s[ 2 2 - 2 4 ] .
Interestingly, a recent trial showed that administration of
anti-VWF aptamer ARC1779, which blocks the VWF-
GPIba interaction, reduced cerebral emboli signals in
patients undergoing carotid endarterectomy [27].
Conclusions
In conclusion, using GPIba/IL4Ra mice, we demon-
strated the crucial role for GPIba in ischemic stroke.
Together with the already existing evidence, our results
further warrant larger translational and clinical studies
to assess the benefits or drawbacks of interfering with
platelet adhesion in stroke.
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